• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Peer Review Process
  • Guide for Authors
  • Submit Manuscript
  • Reviewers
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
Bulletin of Faculty of Pharmacy, Cairo University
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 57 (2019)
Issue Issue 2
Issue Issue 1
Mahfoz, A., Hassanein, N., Shoka, A., Abd El- Latif, H. (2019). Diabetic Nephropathy: Review of Novel Experimental and Clinical Strategies. Bulletin of Faculty of Pharmacy, Cairo University, 57(2), 127-136. doi: 10.21608/bfpc.2019.101869
Amal M. Mahfoz; Nahed M. Hassanein; Afaf A. Shoka; Hekma A. Abd El- Latif. "Diabetic Nephropathy: Review of Novel Experimental and Clinical Strategies". Bulletin of Faculty of Pharmacy, Cairo University, 57, 2, 2019, 127-136. doi: 10.21608/bfpc.2019.101869
Mahfoz, A., Hassanein, N., Shoka, A., Abd El- Latif, H. (2019). 'Diabetic Nephropathy: Review of Novel Experimental and Clinical Strategies', Bulletin of Faculty of Pharmacy, Cairo University, 57(2), pp. 127-136. doi: 10.21608/bfpc.2019.101869
Mahfoz, A., Hassanein, N., Shoka, A., Abd El- Latif, H. Diabetic Nephropathy: Review of Novel Experimental and Clinical Strategies. Bulletin of Faculty of Pharmacy, Cairo University, 2019; 57(2): 127-136. doi: 10.21608/bfpc.2019.101869

Diabetic Nephropathy: Review of Novel Experimental and Clinical Strategies

Article 3, Volume 57, Issue 2, Summer and Autumn 2019, Page 127-136  XML PDF (288.16 K)
Document Type: Original Article
DOI: 10.21608/bfpc.2019.101869
Authors
Amal M. Mahfoz1, 2; Nahed M. Hassanein2; Afaf A. Shoka3; Hekma A. Abd El- Latif1, 3
1Department of Pharmacology and Toxicology, Faculty of Pharmacy, Modern University for Technology and Information, Cairo, Egypt.+
2Department of Developmental Pharmacology, National Organization for Drug Control and Research (NODCAR), Giza, Egypt.
3Faculty of Pharmacy, Cairo University, Cairo, Egypt.
Abstract
Background: Diabetic nephropathy (DN) is considered a severe disorder which affects health worldwide. New more active treatment options are required. Despite a large number of drugs already being available for treatment of hyperglycemia in diabetes, current oral antidiabetic agents often do not provide adequate glycemic control. Renin-angiotensin-aldosterone system (RAAS) blockers are novel agents to slow the progression of DN. Method: The present review provides an overview of recent studies on DN management, especially the use RAAS blockers and their antidiabetic effects. References were mainly identified through PubMed search until December 2016 and backtracking of references in pertinent studies. Results: This review reporting the novel mechanisms and benefits of targeting the RAAS by the use of ACEIs; ARB or direct renin inhibitors in glucose lowering, antioxidant and anti-inflammatory effects and kidney protection. Conclusion: These drugs targeting the RAAS can be used as monotherapy or in combination therapy in hypertensive-diabetic patients to protect them from DN.
Keywords
ACEIs; aliskiren; diabetic nephropathy; RAAS
Statistics
Article View: 217
PDF Download: 370
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.